Blockchain Registration Transaction Record

Oncotelic's Injectable Cancer Drug Boosts Bioavailability to 100%

Oncotelic's Sapu003 injectable Everolimus achieves 100% bioavailability in trials, revolutionizing breast cancer treatment with Deciparticles™ nanotechnology for faster, more effective results.

This development matters because it addresses a critical limitation in cancer treatment - poor drug absorption. Current oral Everolimus only achieves about 10% bioavailability, meaning patients receive a fraction of the intended dose. By increasing bioavailability to near 100%, this technology could dramatically improve treatment outcomes for breast cancer patients, potentially leading to faster response times, more consistent therapeutic effects, and better overall survival rates. The implications extend beyond breast cancer, as this nanoparticle technology could revolutionize how many poorly-absorbed drugs are delivered, potentially transforming treatment protocols across multiple disease areas and improving patient quality of life during cancer therapy.